Abeona Therapeutics Inc. ABEO
2.26 USD -0.04 (-1.83%)
Nov 12, 2026, 10:19 AM EST
2.22 Day range 2.35
2.22 52-week range 7.65
- YTD
- -57.15%
- 1 year
- -54.29%
News
benzinga.com HC Wainwright & Co. Maintains Buy on Abeona Therapeutics, Lowers Price Target to $18 HC Wainwright & Co. analyst Raghuram Selvaraju maintains Abeona Therapeutics (NASDAQ:ABEO) with a Buy and lowers the price target from $20 to $18.
marketbeat.com Abeona Therapeutics Plans New Phase 3 Trial for ABO-801 as ZEVASKYN Launch Expands Abeona Therapeutics NASDAQ: ABEO plans to advance its newly acquired eosinophilic esophagitis drug candidate into another Phase 3 study while expanding the commercial launch of ZEVASKYN, executives…
globenewswire.com Abeona Therapeutics® Announces Participation in Upcoming Investor Conferences CLEVELAND, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that members of its management team will participate in upcoming investor conferences in November…
seekingalpha.com Abeona Therapeutics Inc. (ABEO) Q3 2026 Earnings Call Transcript Abeona Therapeutics Inc. (ABEO) Q3 2026 Earnings Call Transcript
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Edesa Biotech (NASDAQ:EDSA) stock moved upwards by 39.0% to $2.98 during Monday's regular session. The market value of their outstanding shares is at $20.6 million. Heron Therapeutics…
benzinga.com Abeona Therapeutics Acquires Late-Stage Drug Candidate, Secures $30 Million in Equity Financing Abeona beats EPS estimates but misses revenue, acquires ABO-801, raises $30M, and reports growing ZEVASKYN sales and Medicare support.
marketbeat.com What Abeona Therapeutics (ABEO) Said on Its Q3 Earnings Call Abeona Therapeutics NASDAQ: ABEO reported higher ZEVASKYN revenue for the third quarter of 2026 and announced the acquisition of a late-stage drug candidate for eosinophilic esophagitis, as it seeks…
benzinga.com Abeona Therapeutics Acquires ABO-801, Product Candidate For EoE, From Ellodi Pharma, For $20M Equity Consideration; Enters Into Securities Purchase Agreement For $30M Private Placement Financing - Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –– ABO-801 acquired for $20 million equity consideration at closing with no…- benzinga.com Abeona Therapeutics Q3 EPS $(0.08) Beats $(0.15) Estimate, Sales $13.491M Miss $16.484M Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.08) per share which beat the analyst consensus estimate of $(0.15) by 46.67 percent. This is a 20 percent increase over losses of…
globenewswire.com Abeona Therapeutics® Reports Third Quarter 2026 Financial Results and ZEVASKYN® Commercial Progress – Q3 net ZEVASKYN revenue of $13.5 million, up 18% sequentially over Q2 – – 15 ZEVASKYN treatments completed since launch, including six during Q3 – - QTC network expanded to eight sites; four…
globenewswire.com Abeona Therapeutics® Acquires Phase 3-Ready APT-1011, Now ABO-801, and Enters Into Agreement for $30 Million Private Placement - Adds a once-daily, oral therapy candidate for eosinophilic esophagitis with FDA Orphan Drug and Fast Track Designations –
benzinga.com Apple To Rally Around 13%? Here Are 10 Top Analyst Forecasts For Friday Analysts downgraded XENE, NFLX and MGA, while raising price targets for OCS, INSW, ABEO and STNG.
benzinga.com Abeona Stands to Collect Royalties After Ultragenyx's FDA Approval — Here's the Rest of the Week Abeona Therapeutics had a busy week with treatment network expansion, an FDA approval tied to a licensed therapy and fresh analyst coverage.
benzinga.com Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Raises Price Target to $30 Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and raises the price target from $28 to $30.
benzinga.com Ultragenyx Pharmaceutical Says FDA Grants Standard Full Approval Of FAYUVI For Treatment Of Pediatric Patients With Mucopolysaccharidosis Type IIIA FAYUVI is a highly anticipated, first-ever treatment option with the potential to stop or slow the devastating, irreversible neurologic progression and loss of function associated with Sanfilippo…
benzinga.com Roth Capital Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $17 Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Abeona Therapeutics (NASDAQ:ABEO) with a Buy rating and announces Price Target of $17.
benzinga.com Oppenheimer Maintains Outperform on Abeona Therapeutics, Lowers Price Target to $21 Oppenheimer analyst Jeff Jones maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and lowers the price target from $22 to $21.
benzinga.com Abeona Therapeutics Q2 2026 Earnings Call Transcript Abeona Therapeutics (NASDAQ:ABEO) held its second-quarter earnings conference call on Thursday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For…
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers Liminatus Pharma (NASDAQ:LIMN) stock moved upwards by 55.9% to $0.17 during Thursday's pre-market session. The company's market cap stands at $7.2 million. LENSAR (NASDAQ:LNSR) shares…- benzinga.com Abeona Therapeutics Q2 EPS $(0.35) Misses $(0.23) Estimate, Sales $11.380M Miss $12.239M Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.35) per share which missed the analyst consensus estimate of $(0.23) by 52.17 percent. This is a 5.41 percent increase over losses…
benzinga.com Abeona Therapeutics Says CMS Granted New Technology Add-On Payment Status For ZEVASKYN Under Fiscal Year 2027 Hospital Inpatient Prospective Payment System Final Rule The Centers for Medicare & Medicaid Services (CMS) has granted New Technology Add-On Payment (NTAP) status for ZEVASKYN (prademagene zamikeracel) under the Fiscal Year 2027 Hospital Inpatient…- benzinga.com Abeona Therapeutics Activates Cincinnati Children’s As Seventh Qualified Treatment Center For Administration Of ZEVASKYN To Treat Wounds In Patients With Recessive Dystrophic Epidermolysis Bullosa Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced the activation of Cincinnati Children’s…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
- benzinga.com Abeona Therapeutics Q1 2026 Earnings Call: Complete Transcript
benzinga.com Abeona Reports Strong Q1 Revenue, Expands Treatment Center Network Abeona Therapeutics Inc. (NASDAQ: ABEO) reported first-quarter earnings Wednesday before the market opened. Here's a rundown of the report.
benzinga.com Abeona Therapeutics Q1 EPS $(0.30) Beats $(0.35) Estimate, Sales $8.720M Beat $4.572M Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.35) by 14.29 percent. This is a 25 percent decrease over losses of…
benzinga.com Earnings Scheduled For May 13, 2026 - benzinga.com Abeona Therapeutics Activates Children's Hospital Of Philadelphia As Sixth Qualified Treatment Center To Treat ZEVASKYN Gene-Modified Cellular Sheets Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing genetic medicines for serious diseases with high unmet need, today announced activation of the…
- benzinga.com HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
- benzinga.com Abeona Therapeutics Q4 EPS $(0.34) Beats $(0.36) Estimate, Sales $5.420M Beat $5.270M Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.36) by 4.49 percent. This is a 142.86 percent decrease over losses of…
- benzinga.com Earnings Scheduled For March 17, 2026
- benzinga.com HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session - benzinga.com Abeona Therapeutics Q3 EPS $(0.10) Beats $(0.29) Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.29) by 65.52 percent. This is a 84.13 percent increase over losses of…
- benzinga.com Earnings Scheduled For November 12, 2025
benzinga.com What to Expect from Abeona Therapeutics's Earnings - benzinga.com Abeona Secures Permanent CMS J-Code J3389 For ZEVASKYN Gene Therapy In Recessive Dystrophic Epidermolysis Bullosa; New J-Code Becomes Effective January 1, 2026 Abeona Therapeutics Inc. (NASDAQ:ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced that the Centers for Medicare and…
benzinga.com Abeona Therapeutics Announced That Its ABO-503 Gene Therapy For X-linked Retinoschisis Has Been Selected To Participate In FDA Rare Disease Endpoint Advancement Pilot Program ABO-503 is composed of a functional human RS1 gene packaged in the novel AIM™ capsid AAV204. ABO-503 has shown preclinical efficacy following delivery to the retina in a mouse model of XLRS.…- benzinga.com HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
- benzinga.com HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $20 Price Target HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Buy and maintains $20 price target.
- benzinga.com Oppenheimer Maintains Outperform on Abeona Therapeutics, Raises Price Target to $20 Oppenheimer analyst Andreas Argyrides maintains Abeona Therapeutics (NASDAQ:ABEO) with a Outperform and raises the price target from $19 to $20.
- benzinga.com Abeona Therapeutics Q2 EPS $1.71 Beats $(0.39) Estimate Abeona Therapeutics (NASDAQ:ABEO) reported quarterly earnings of $1.71 per share which beat the analyst consensus estimate of $(0.39) by 543.01 percent. This is a 757.69 percent increase over losses…
benzinga.com PDD Holdings Posts Weak Results, Joins EHang Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session 
benzinga.com Why E2open Shares Are Trading Higher By 25%; Here Are 20 Stocks Moving Premarket - benzinga.com Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
- benzinga.com Why Hibbett Shares Are Trading Higher By 18%; Here Are 20 Stocks Moving Premarket
- benzinga.com Calix Reports Mixed Results, Joins Cadence Design Systems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session